HC Wainwright Has Positive Estimate for Clene Q2 Earnings

Clene Inc. (NASDAQ:CLNN) – Equities research analysts at HC Wainwright boosted their Q2 2026 EPS estimates for Clene in a research note issued on Thursday, May 14th. HC Wainwright analyst J. Pantginis now expects that the company will post earnings per share of ($0.35) for the quarter, up from their prior estimate of ($0.48). HC Wainwright currently has a “Buy” rating and a $31.00 price objective on the stock. The consensus estimate for Clene’s current full-year earnings is ($1.99) per share. HC Wainwright also issued estimates for Clene’s Q3 2026 earnings at ($0.46) EPS, Q4 2026 earnings at ($0.58) EPS, FY2026 earnings at ($1.70) EPS, FY2027 earnings at ($0.95) EPS and FY2028 earnings at ($0.62) EPS.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.05). The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.05 million.

A number of other research firms have also weighed in on CLNN. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Clene in a research note on Friday, March 13th. Weiss Ratings raised shares of Clene from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 8th. D. Boral Capital reaffirmed a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Monday, May 4th. Finally, Roth Mkm reissued a “buy” rating on shares of Clene in a research report on Thursday. Six analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $33.25.

Clene Trading Down 4.9%

Clene stock opened at $6.79 on Tuesday. Clene has a 1-year low of $2.28 and a 1-year high of $13.50. The firm has a market capitalization of $86.78 million, a price-to-earnings ratio of -2.12 and a beta of 0.89. The firm’s fifty day moving average price is $6.04 and its two-hundred day moving average price is $6.36.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CLNN. Jones Financial Companies Lllp bought a new stake in shares of Clene during the 3rd quarter worth $29,000. Jane Street Group LLC purchased a new position in shares of Clene in the 2nd quarter worth about $47,000. State Street Corp grew its position in Clene by 138.4% during the fourth quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after buying an additional 17,300 shares during the period. PEAK6 LLC bought a new position in Clene during the fourth quarter valued at about $294,000. Finally, Lunt Capital Management Inc. grew its position in Clene by 2.5% during the third quarter. Lunt Capital Management Inc. now owns 52,260 shares of the company’s stock valued at $315,000 after buying an additional 1,250 shares during the period. 23.28% of the stock is owned by institutional investors.

Insider Buying and Selling at Clene

In related news, major shareholder Chidozie Ugwumba sold 73,296 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $6.20, for a total transaction of $454,435.20. Following the transaction, the insider directly owned 103,417 shares of the company’s stock, valued at $641,185.40. This trade represents a 41.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold 327,677 shares of company stock worth $2,043,481 over the last 90 days. 28.30% of the stock is owned by company insiders.

About Clene

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).